CLINICAL TRIALS PROFILE FOR ARAZLO
✉ Email this page to a colleague
All Clinical Trials for ARAZLO
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05704114 ↗ | Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne | Completed | Dr. Emmy Graber | Phase 4 | 2021-02-01 | The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ARAZLO
Condition Name
Clinical Trial Locations for ARAZLO
Trials by Country
Clinical Trial Progress for ARAZLO
Clinical Trial Phase
Clinical Trial Sponsors for ARAZLO
Sponsor Name